NZ523725A - Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)-amino)-ethoxy]benzyl]thiazolidine-2-4-dione - Google Patents

Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)-amino)-ethoxy]benzyl]thiazolidine-2-4-dione

Info

Publication number
NZ523725A
NZ523725A NZ523725A NZ52372598A NZ523725A NZ 523725 A NZ523725 A NZ 523725A NZ 523725 A NZ523725 A NZ 523725A NZ 52372598 A NZ52372598 A NZ 52372598A NZ 523725 A NZ523725 A NZ 523725A
Authority
NZ
New Zealand
Prior art keywords
compound
pharmaceutically acceptable
composition
tablet
acceptable form
Prior art date
Application number
NZ523725A
Other languages
English (en)
Inventor
Jai Patel
Hamish Ross
Jeffrey Roger Granett
Robin Price
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712851.6A external-priority patent/GB9712851D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NZ523725A publication Critical patent/NZ523725A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ523725A 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)-amino)-ethoxy]benzyl]thiazolidine-2-4-dione NZ523725A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711683.4A GB9711683D0 (en) 1997-06-05 1997-06-05 Composition
GBGB9712851.6A GB9712851D0 (en) 1997-06-18 1997-06-18 Composition

Publications (1)

Publication Number Publication Date
NZ523725A true NZ523725A (en) 2004-09-24

Family

ID=26311662

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ523725A NZ523725A (en) 1997-06-05 1998-06-02 Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)-amino)-ethoxy]benzyl]thiazolidine-2-4-dione
NZ513922A NZ513922A (en) 1997-06-05 2001-09-03 Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ513922A NZ513922A (en) 1997-06-05 2001-09-03 Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione

Country Status (29)

Country Link
EP (1) EP0998284A1 (pt)
JP (1) JP2001521553A (pt)
KR (1) KR20010013410A (pt)
CN (3) CN1526391A (pt)
AP (1) AP1214A (pt)
AR (2) AR008198A1 (pt)
AU (1) AU8215098A (pt)
BG (1) BG104048A (pt)
BR (1) BR9810405A (pt)
CA (2) CA2333352A1 (pt)
CO (1) CO4940400A1 (pt)
DZ (1) DZ2510A1 (pt)
EA (1) EA002384B1 (pt)
GB (1) GB9711683D0 (pt)
HU (1) HUP0004070A3 (pt)
ID (1) ID24264A (pt)
IL (1) IL133074A0 (pt)
MX (1) MXPA99011322A (pt)
NO (2) NO995938L (pt)
NZ (2) NZ523725A (pt)
OA (1) OA11306A (pt)
PE (1) PE78899A1 (pt)
PL (1) PL337201A1 (pt)
SK (1) SK164899A3 (pt)
TR (2) TR200002790T2 (pt)
TW (1) TW570797B (pt)
UY (1) UY25032A1 (pt)
WO (1) WO1998055122A1 (pt)
ZA (2) ZA984826B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1598A (en) * 1999-04-23 2006-04-26 Smithkline Beecham Plc Polymorph of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173434B1 (en) 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
EP2270007A1 (en) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
WO2015008234A1 (en) * 2013-07-17 2015-01-22 Glenmark Pharmaceuticals S.A. Bicyclic heterocyclic compounds as ror gamma modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
SK16498A3 (en) * 1995-08-10 1999-03-12 Warner Lambert Co A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
WO1997018811A1 (en) * 1995-11-17 1997-05-29 Warner-Lambert Company A method of treating myotonic dystrophy
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
BR9710272A (pt) * 1996-07-12 1999-08-10 Smithkline Beecham Plc Novo tratamento de resisténcia a leptina

Also Published As

Publication number Publication date
CN1526391A (zh) 2004-09-08
NO995938L (no) 2000-02-02
CA2292629A1 (en) 1998-12-10
TR199902963T2 (xx) 2000-02-21
AR008198A1 (es) 1999-12-29
OA11306A (en) 2003-10-22
UY25032A1 (es) 1998-11-26
PL337201A1 (en) 2000-08-14
BG104048A (bg) 2000-07-31
BR9810405A (pt) 2000-08-29
GB9711683D0 (en) 1997-08-06
DZ2510A1 (fr) 2003-01-25
CO4940400A1 (es) 2000-07-24
ID24264A (id) 2000-07-13
CA2292629C (en) 2004-01-06
TW570797B (en) 2004-01-11
EA002384B1 (ru) 2002-04-25
WO1998055122A1 (en) 1998-12-10
ZA9811572B (en) 1999-07-22
IL133074A0 (en) 2001-03-19
HUP0004070A2 (hu) 2002-02-28
CN1112926C (zh) 2003-07-02
TR200002790T2 (tr) 2001-11-21
KR20010013410A (ko) 2001-02-26
MXPA99011322A (es) 2004-12-02
SK164899A3 (en) 2000-11-07
PE78899A1 (es) 1999-10-22
AU8215098A (en) 1998-12-21
AR015120A1 (es) 2001-04-18
NO995938D0 (no) 1999-12-03
NZ513922A (en) 2001-09-28
NO20040738L (no) 2000-02-02
EP0998284A1 (en) 2000-05-10
CN1259050A (zh) 2000-07-05
AP1214A (en) 2003-10-08
ZA984826B (en) 1999-08-03
EA199901116A1 (ru) 2000-06-26
AP9901696A0 (en) 1999-12-31
CN1430959A (zh) 2003-07-23
CA2333352A1 (en) 1998-12-10
JP2001521553A (ja) 2001-11-06
HUP0004070A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
EP1292300B1 (en) Combinations od dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment fo diabete mellitus
SK286029B6 (sk) Farmaceutický prostriedok a jeho použitie
CA2292629C (en) Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US7045633B2 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20040082621A1 (en) Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione
AP1287A (en) Treatment of diabetes with rosiglitazone and insulin.
US6664278B2 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
EP0999845B1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
AU743269B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
US20040106543A1 (en) Treatment of diabetes with rosiglitazone and insulin
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
AU9513401A (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl) amino)ethoxy)benzyl)thiazolidine-2,4-dione
AU778947B2 (en) Treatment of diabetes with thiazolidinedione and metformin
AU783539B2 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
CZ432299A3 (cs) Kompozice obsahující 5-[4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl]thiazolidin-2,4-dion
NZ518076A (en) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (BRL49653) for treating non-insulin dependent diabetes (NIDDM)
AU774613B2 (en) Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
AU1552102A (en) Treatment of diabetes with rosiglitazone and insulin
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
NZ520542A (en) Treatment of diabetes with thiazolidinedione and metformin

Legal Events

Date Code Title Description
PSEA Patent sealed